Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Does the effectiveness of bicalutamide in reducing the risk of prostate cancer progression vary with lymph node status?

Nature Clinical Practice Urology volume 1, pages 18–19 (2004)Cite this article

boxed-textIversen P et al. for the Casodex Early Prostate Cancer Trialists' Group (2004) Is the efficacy of hormonal therapy affected by lymph node status? Data from the bicalutamide (Casodex) Early Prostate Cancer program. Urology 63: 928–933

Until trial results demonstrate clear evidence of a survival advantage, clinicians should exercise caution in utilizing bicalutamide as monotherapy for the treatment of early recurrent prostate cancer

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Crawford ED et al. (1989) A controlled trial of leuprolide with and without flutamide in prostatic cancer. N Engl J Med 321: 419–424

    Article  CAS  Google Scholar 

  2. Eisenberger MA et al. (1998) Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 339: 1036–1042

    Article  CAS  Google Scholar 

  3. Seidenfeld J et al. (2000) Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 132: 566–577

    Article  CAS  Google Scholar 

  4. Messing EM et al. (1999) Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341: 1781–1788

    Article  CAS  Google Scholar 

  5. Bolla M et al. (2002) Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360: 103–106

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Suzanne Farley, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Professor and Chief of Urology at the University of Connecticut Health Center.,

    Peter Albertsen

Authors
  1. Peter Albertsen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter Albertsen.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Albertsen, P. Does the effectiveness of bicalutamide in reducing the risk of prostate cancer progression vary with lymph node status?. Nat Rev Urol 1, 18–19 (2004). https://doi.org/10.1038/ncpuro0002

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpuro0002

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing